CJC-1295 (no DAC)

PeptideXpo buyer fit

Overview

CJC-1295 without DAC (also known as Modified GRF 1-29 or ModGRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions (Ala2→D-Ala, Asn8→Gln, Gly15→Ala, Met27→Leu) that confer protection against DPP-4 cleavage and serum protease degradation. The molecule signals through the GHRH receptor to produce pulsatile GH release that closely resembles physiological secretion patterns, distinct from the more sustained drug-affinity-complex (DAC) version, which has substantially longer plasma half-life via covalent albumin binding. PeptideXpo supplies CJC-1295 no-DAC as the acetate salt, lyophilized, ≥99.0% HPLC. The no-DAC form is most commonly paired with a GHSR-pathway agonist (Ipamorelin, GHRP-2, or GHRP-6) in GH-axis research and compounding workflows, the dual-pathway combination produces additive GH-release signals beyond either component alone, and the canonical CJC-1295 + Ipamorelin blend is one of the most-requested SKUs in our catalog (sold as the dedicated cjc-1295-ipamorelin combination vial). For the full pharmacology rationale of the dual-pathway combination, see our [CJC-1295 + Ipamorelin guide](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide). Compounding pharmacies typically dispense from 2 mg or 5 mg vials; research labs often prefer the 5 mg or 10 mg fills for in vivo dose-titration work.

Who buys this, and why

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS

No single public CAS for the without-DAC (Mod-GRF 1-29) form; identity per batch COA

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

7–14 days

Storage

-20°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion (acetate vs TFA)
• Sterile-fill release pack (sterility, CCI, fill-weight)
• Bacterial endotoxin (LAL, USP <85>)
• Stability data on request
• SDS / MSDS

Regulatory note

Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Frequently asked questions